Douglas S Micalizzi
Overview
Explore the profile of Douglas S Micalizzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
Nat Commun
. 2025 Jan;
16(1):32.
PMID: 39746954
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we...
2.
Folkerts E, Pelletier R, Chung D, Goldstein S, Micalizzi D, Shannon K, et al.
Genet Med Open
. 2024 Dec;
1(1):100819.
PMID: 39669243
Purpose: Given limited ambulatory access to genetics specialists, innovative service delivery solutions are needed. Electronic consultation (e-consult) programs are growing to connect clinicians to specialists. We explored the utilization and...
3.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
bioRxiv
. 2024 Apr;
PMID: 38559183
Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility...
4.
Micalizzi D, Sequist L, Haber D
Science
. 2024 Jan;
383(6681):368-370.
PMID: 38271495
AI-based risk assessment may enable personalized blood-based multicancer screening.
5.
Brett J, Dubash T, Johnson G, Niemierko A, Mariotti V, Kim L, et al.
JCO Precis Oncol
. 2023 May;
7:e2200532.
PMID: 37141550
Purpose: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), first-line treatment is endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibition (CDK4/6i)....
6.
Folkerts E, Pelletier R, Chung D, Goldstein S, Micalizzi D, Shannon K, et al.
medRxiv
. 2023 Feb;
PMID: 36798390
Innovative service delivery models are needed to increase access to genetics specialists. Electronic consultation (e-Consult) programs can connect clinicians with specialists. At Massachusetts General Hospital, an e-Consult service was created...
7.
Micalizzi D, Che D, Nicholson B, Edd J, Desai N, Lang E, et al.
Proc Natl Acad Sci U S A
. 2022 Oct;
119(43):e2209563119.
PMID: 36256815
The successful application of antibody-based therapeutics in either primary or metastatic cancer depends upon the selection of rare cell surface epitopes that distinguish cancer cells from surrounding normal epithelial cells....
8.
Karabacak N, Zheng Y, Dubash T, Burr R, Micalizzi D, Wittner B, et al.
Cancer Res
. 2022 Jan;
82(6):1084-1097.
PMID: 35045985
Significance: Single-cell mass cytometry analyses provide insights into the differences in kinase activities across tumor compartments and cell states, which contribute to heterogeneous responses to targeted therapies.
9.
Micalizzi D, Ebright R, Haber D, Maheswaran S
Cancer Res
. 2021 Jan;
81(3):517-524.
PMID: 33479028
Deregulation of the mRNA translational process has been observed during tumorigenesis. However, recent findings have shown that deregulation of translation also contributes specifically to cancer cell spread. During metastasis, cancer...
10.
Ebright R, Zachariah M, Micalizzi D, Wittner B, Niederhoffer K, Nieman L, et al.
Nat Commun
. 2020 Dec;
11(1):6311.
PMID: 33298946
Blood-borne metastasis to the brain is a major complication of breast cancer, but cellular pathways that enable cancer cells to selectively grow in the brain microenvironment are poorly understood. We...